Skip to content

Effect and central regulatory mechanism of transcutaneous vagus nerve stimulation in the treatment of inflammatory bowel disease and irritable bowel syndrome

Effect and central regulatory mechanism of transcutaneous vagus nerve stimulation in the treatment of inflammatory bowel disease and irritable bowel syndrome

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068776
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease, irritable bowel syndrome.

Interventions

Treatment group:transcutaneous vagus nerve stimulation
Sham-Stiming Group:sham-taVNS
Control Group:no

Sponsors

The People's Hospital of Guangxi Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a. age 18 to 65 years b. meet diagnostic criteria for inflammatory bowel disease and irritable bowel syndrome; c. right hand; d. Drugs that can be discontinued for gastrointestinal disorders in the first week of the study.

Exclusion criteria

Exclusion criteria: a. Severe comorbidities (e.g., uncontrolled hypertension or gastrointestinal bleeding, severe cardiopulmonary and encephalopathy) and coronary heart disease; b. autoimmune diseases affecting gastrointestinal motility, such as scleroderma and dermatomyositis; c. history of gastrointestinal surgery; d. Organic lesions of the stomach and intestines of any grade such as peptic ulcers and gastric tumors; e. presence of infectious lesions such as non-inflammatory bowel diseases such as enteric tuberculosis; f. Other functional gastrointestinal disorders are present; g. taking drugs for gastrointestinal disorders, drugs that affect GI motility, or drugs that cannot be withdrawn within 1 week before recruitment; h. unable to cooperate with the appropriate assessment and examination; i. Contraindications to magnetic resonance imaging (e.g., failure to remove metal dentures or other metal implants, claustrophobia, etc.).

Design outcomes

Primary

MeasureTime frame
IBS-SSS;QOL;Stool Characteristics Score;Structural Magnetic Resonance Imaging;DTI;fMRI;MRS;

Secondary

MeasureTime frame
HAMD;HAMA;PHQ-9;GAD-7;PSQI;

Countries

China

Contacts

Public ContactBei Peng

The People's Hospital of Guangxi Autonomous Region

pengbei2002@163.com+86 13768319364

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026